Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9432581 | 0.67 | — | — | |
| Quinazolinone SCHEMBL164234 | 0.67 | PI4KA (0.56) | ALDH1A1HTTMAPTTDP1 | |
| SCHEMBL2538320 | 0.67 | KDM4E (0.33) | KDM4EALDH1A1HTTNCOA1NCOA3 | |
| SCHEMBL18013039 | 0.67 | EGFR (0.42) | IRAK4 | |
| SCHEMBL11814148 | 0.66 | SMN1; SMN2 (0.53) | KDM4EALDH1A1HTTMAPTHPGD | |
| SCHEMBL1192531 | 0.64 | PARP1 (0.47) | KDM4EALDH1A1HTTMAPTHPGD | |
| SCHEMBL8813539 | 0.64 | MAPK13 (0.34) | HPGD | |
| SCHEMBL1011251 | 0.64 | IRAK4 (0.39) | IRAK4 | |
| SCHEMBL8807100 | 0.64 | EGFR (0.41) | KDM4EALDH1A1HTTMAPTIRAK4 | |
| SCHEMBL5453911 | 0.64 | EGFR (0.46) | KDM4EALDH1A1HTTMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4591866-A1 | USE OF HYPOXIA-ACTIVATED COMPOUND IN PREPARATION OF MEDICAMENT FOR TREATING CANCER PATIENT | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-07-30 | — | — | EP | disclosed |
| CN-119894521-A | Use of hypoxia-activated compounds for the preparation of a medicament for the treatment of cancer patients | 深圳艾欣达伟医药科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024061346-A1 | USE OF HYPOXIA-ACTIVATED COMPOUND IN PREPARATION OF MEDICAMENT FOR TREATING CANCER PATIENT | 深圳艾欣达伟医药科技有限公司 | 2024-03-28 | — | — | WO | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDM4E 3645/4885ALDH1A1 1048/4885HTT 4587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.